Breaking News

Paladin Labs Acquires Allon Therapeutics

July 17, 2013

Becomes the sole shareholder of Allon

Paladin Labs, Inc. has acquired Allon Therapeutics in accordance with the Order for Reorganization in Allon's proposal proceedings under Canada’s Bankruptcy and Insolvency Act and Business Corporations Act, becoming the sole shareholder of Allon.
 
In May, Allon and Paladin entered an agreement under which Paladin would obtain all outstanding shares of Allon through a reorganization of Allon's share structure and make a cash payment to Allon of $900,000.
 
Immediately prior to Paladin becoming the sole shareholder of Allon, all existing issued and outstanding shares and other securities of Allon were cancelled without payment or other consideration. As the sole shareholder of Allon, Allon will cease being a reporting issuer in Canada.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.